Ask AI
ProCE Banner Activity

CE

Improving Outcomes With Oral SERDs in MBC: Case Challenges and Skill-Building Strategies for the Advanced Practice Provider

Video

Watch this on-demand webcast to discover the latest evidence and best practices for optimizing oral next-generation estrogen receptor (ER)–directed therapies in ER-positive/HER2-negative metastatic breast cancer through key clinical trial data presented alongside guidance on treatment selection, adverse event recognition and management, patient counseling, adherence, and more. Viewers will learn how to translate biomarker and efficacy data into individualized treatment decisions while helping patients navigate the practical and safety considerations of oral endocrine therapy.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: November 04, 2026

Expiration: May 03, 2027

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca, Lilly, and Stemline Therapeutics, Inc.

AstraZeneca

Lilly

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who care for patients with HR-positive/HER2-negative metastatic breast cancer.

Program Learning Goal

This activity aims to equip learners with the education, skills, and resources needed to employ shared decision-making and communication strategies to improve adherence, manage treatment-related adverse events, and counsel patients initiating or switching to oral SERD therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess for ESR1 mutations and other actionable genetic alterations in patients with progressive or recurrent ER-positive/HER2-negative MBC consistent with current evidence and local expert guidance

  • Integrate recent evidence for next-generation SERDs into care for patients with endocrine-resistant ER-positive/HER2-negative MBC, considering patient/disease factors, evidence, and local expert guidance

  • Appraise emerging evidence for novel next-generation SERDs and note clinical implications for management of ER-positive/HER2-negative MBC

Financial Disclosures

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jamie L. Carroll, MSN, APRN, CNP: consultant/advisor/speaker: Amplity, AstraZeneca, Novartis.

Amy Goodrich, CRNP: advisor: AbbVie, Incyte, Lilly.

Cierra K. Ryan, PA-C, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 04, 2026, through May 03, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until May 03, 2027. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

A logo for a credit companyAI-generated content may be incorrect.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.